SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Escalating IranStrait of Hormuz tensions and oil-price volatility are driving attention to Carnival, with traders debating the impact of higher fuel costs and broader travel-sector risk. Bulls argue that strong cruise demand, debt reduction, buybacks and the reinstated dividend make the shares undervalued, while bears focus on geopolitical uncertainty, weak price action and potential further selling.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

FDA approval of Rasonque (daraxonrasib) for metastatic pancreatic cancer is driving attention, with traders highlighting its first-in-class RAS-targeted mechanism and strong survival results as a potential commercial breakthrough. Despite bullish views on the launch and broader oncology pipeline, some investors are debating the stocks elevated valuation, treatment cost and access, while others interpret the muted pullback as profit-taking or a sell-the-news reaction.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish BMF short report criticizing SELLASs REGAL Phase 3 design, statistical power, dilution and valuation triggered the selloff and intensified debate ahead of the 80th event and topline data. Bulls largely dismiss the report as a disclosed short-side thesis and point to prolonged patient survival and prior interim reviews, while bears remain concerned that the delayed event and quiet period could precede unfavorable results.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Geopolitical headlines around the Iran conflict, Strait of Hormuz access, and potential peace or supply agreements are driving volatile crude-oil expectations and attention to SCOs inverse exposure. Traders are split between betting on de-escalation, rising production, and weaker demand to push oil lower, and warning that continued disruptions could keep crude elevated; many also debate SCOs daily reset and decay, which can limit tracking over time.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Ongoing U.S.-Iran tensions and uncertainty over Strait of Hormuz shipping are driving attention to crude oil and UCO, with traders reacting to shifting ceasefire and reopening expectations. The community is divided between bulls anticipating supply disruptions and shortages and bears pointing to oversupply, rising inventories, recovering flows, and weaker demand.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Anticipated LUNC supply burnslinked by traders to Binance activity, the Jane Street legal dispute, and Market Module 2.0along with a possible USTC repeg are driving bullish speculation around a Terra Classic recovery. Skeptics point to LUNCs large supply, thin liquidity, repeated pullbacks, and unverified exchange-listing or burn claims, keeping the debate focused on whether the rally is sustainable.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

A sizable at-the-market share offering announced around the quarterly results has become the dominant catalyst, with traders concerned about dilution, potential selling pressure, and uncertainty over why the company is raising cash despite strong operating performance. Some investors view the selloff as a temporary overreaction and remain bullish on Innodatas AI-data growth, while others are focused on customer concentration and bearish technical momentum.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Q2 earnings have driven attention, with traders divided between concerns over weaker headline revenue and EPS and optimism that hedge-related losses masked healthy operations, improving adjusted EBITDA, and reaffirmed guidance. Bulls continue to cite Vistras long-term power agreements and exposure to AI/data-center electricity demand, while the stocks persistent downtrend has fueled skepticism.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Managements profitability and plan to use Orladeyo cash flow for additional rare-disease acquisitions are driving attention, alongside expectations for navenibart and BCX17725 pipeline progress. Traders remain divided between viewing BioCryst as undervalued and a potential takeover candidate versus concerns about competition from Pharvaris, dilution, and persistently weak price action; takeover speculation is unconfirmed.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NNE is drawing attention as part of a broader nuclear/SMR rotation tied to AI data-center power demand, U.S. nuclear policy, and recent company developments including Air Force work, regulatory progress, and fuel/logistics initiatives. Traders remain divided, with bulls citing long-term commercialization potential and bears pointing to its pre-revenue status, execution risk, dilution concerns, and sector-wide weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
